• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表达 G2019S 突变 LRRK2 的转基因小鼠中多巴胺能神经元丢失、神经突复杂性降低和自噬异常。

Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

机构信息

Brain Mind Institute, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

出版信息

PLoS One. 2011 Apr 6;6(4):e18568. doi: 10.1371/journal.pone.0018568.

DOI:10.1371/journal.pone.0018568
PMID:21494637
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3071839/
Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.

摘要

LRRK2 基因中的突变导致迟发性、常染色体显性家族性帕金森病 (PD),也与特发性 PD 有关。LRRK2 突变是 PD 最常见的病因,其临床和神经化学特征与特发性疾病基本无法区分。目前,表达野生型或致病突变型 LRRK2 的转基因小鼠未能产生明显的神经退行性变,尽管观察到黑质纹状体多巴胺能神经传递的异常。在这里,我们描述了表达家族性 PD 突变 R1441C 和 G2019S 的人类 LRRK2 的转基因小鼠的开发和特征。我们的研究表明,G2019S 突变型 LRRK2 的表达以年龄依赖性方式诱导黑质纹状体通路多巴胺能神经元的退化。此外,我们观察到老年 G2019S LRRK2 小鼠大脑中存在自噬和线粒体异常,以及培养的多巴胺能神经元的神经突复杂性明显降低。这些新的 LRRK2 转基因小鼠将为理解家族性突变引发神经元变性和 PD 的机制提供重要工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/fb1cc9211e70/pone.0018568.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/d54aa1fe40a4/pone.0018568.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/d16275144a0f/pone.0018568.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/f0aeeac87f89/pone.0018568.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/07b6b3ae5187/pone.0018568.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/3df7b92918af/pone.0018568.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/14cb2d258287/pone.0018568.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/fb1cc9211e70/pone.0018568.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/d54aa1fe40a4/pone.0018568.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/d16275144a0f/pone.0018568.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/f0aeeac87f89/pone.0018568.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/07b6b3ae5187/pone.0018568.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/3df7b92918af/pone.0018568.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/14cb2d258287/pone.0018568.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7216/3071839/fb1cc9211e70/pone.0018568.g007.jpg

相似文献

1
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.表达 G2019S 突变 LRRK2 的转基因小鼠中多巴胺能神经元丢失、神经突复杂性降低和自噬异常。
PLoS One. 2011 Apr 6;6(4):e18568. doi: 10.1371/journal.pone.0018568.
2
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.帕金森病相关的R1441C型亮氨酸重复激酶2(LRRK2)在小鼠中脑多巴胺能神经元中的条件性表达会导致核异常但无神经退行性变。
Neurobiol Dis. 2014 Nov;71:345-58. doi: 10.1016/j.nbd.2014.08.027. Epub 2014 Aug 29.
3
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.帕金森病相关的富含亮氨酸重复激酶2 G2019S错义突变在中脑多巴胺能神经元中的选择性表达会损害多巴胺释放及多巴胺能基因表达。
Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249. Epub 2015 Jun 29.
4
Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.细菌人工染色体转基因G2019S富含亮氨酸重复激酶2大鼠的行为、神经化学和病理学改变
Neurobiol Aging. 2015 Jan;36(1):505-18. doi: 10.1016/j.neurobiolaging.2014.07.011. Epub 2014 Jul 15.
5
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.(G2019S) LRRK2 激活 MKK4-JNK 通路,导致 PD 转基因小鼠模型中 SN 多巴胺能神经元的变性。
Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.
6
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.帕金森病相关的G2019S LRRK2诱导的多巴胺能神经变性依赖于激酶和GTP酶活性。
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17296-17307. doi: 10.1073/pnas.1922184117. Epub 2020 Jul 6.
7
(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.(G2019S)LRRK2导致帕金森病转基因小鼠中黑质致密部多巴胺能神经元的早期功能障碍以及皮质纹状体长时程抑制受损。
Neurobiol Dis. 2014 Aug;68:190-9. doi: 10.1016/j.nbd.2014.04.021. Epub 2014 May 14.
8
Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.突变 LRRK2 在成年大鼠中的时间表达会损害多巴胺摄取。
Int J Biol Sci. 2011;7(6):753-61. doi: 10.7150/ijbs.7.753. Epub 2011 Jun 9.
9
Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).Rac1 蛋白挽救了 G2019S 亮氨酸丰富重复激酶 2(LRRK2)引起的神经突回缩。
J Biol Chem. 2011 May 6;286(18):16140-9. doi: 10.1074/jbc.M111.234005. Epub 2011 Mar 16.
10
No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.在表达野生型或G2019S突变型LRRK2生理水平的转基因小鼠以及人成纤维细胞中,未发现多巴胺能细胞丢失或细胞骨架功能改变。
PLoS One. 2015 Apr 1;10(4):e0118947. doi: 10.1371/journal.pone.0118947. eCollection 2015.

引用本文的文献

1
Low-frequency genetic variants in GAK enhance Golgi function and protect against Parkinson's disease.GAK基因中的低频遗传变异增强高尔基体功能并预防帕金森病。
medRxiv. 2025 Aug 15:2025.08.13.25333123. doi: 10.1101/2025.08.13.25333123.
2
Role of LRRK2 in axonal transport and Parkinson's disease.富亮氨酸重复激酶2(LRRK2)在轴突运输及帕金森病中的作用
Biochem J. 2025 Jun 25;482(13):BCJ20253133. doi: 10.1042/BCJ20253133.
3
Temporal progression of pathological features in an α-synuclein overexpression model of Parkinson's disease.帕金森病α-突触核蛋白过表达模型中病理特征的时间进程

本文引用的文献

1
A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.LRRK2 相关帕金森病 G2019S 突变诱导的进行性黑质神经退行性变大鼠模型。
J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.
2
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.富含亮氨酸重复激酶-2 抑制剂可预防帕金森病模型。
Nat Med. 2010 Sep;16(9):998-1000. doi: 10.1038/nm.2199. Epub 2010 Aug 22.
3
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.
Brain Struct Funct. 2025 Jun 9;230(6):91. doi: 10.1007/s00429-025-02959-9.
4
Roles of LRRK2 and its orthologs in protecting against neurodegeneration and neurodevelopmental defects.富含亮氨酸重复激酶2(LRRK2)及其直系同源物在预防神经退行性变和神经发育缺陷中的作用。
Front Cell Dev Biol. 2025 Apr 30;13:1569733. doi: 10.3389/fcell.2025.1569733. eCollection 2025.
5
The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism.纯合型LRRK2.p.N1437D点突变小鼠是帕金森病的一种新型模型。
NPJ Parkinsons Dis. 2025 Mar 28;11(1):61. doi: 10.1038/s41531-025-00905-4.
6
Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.短期脂多糖治疗可导致携带LRRK2 G2019S突变的基因敲入小鼠的星形胶质细胞激活,而多巴胺能神经元未丢失。
BMC Neurosci. 2025 Mar 4;26(1):19. doi: 10.1186/s12868-025-00939-7.
7
Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.帕金森病毒性模型中的单胺氧化酶抑制剂
Int J Mol Sci. 2025 Jan 31;26(3):1248. doi: 10.3390/ijms26031248.
8
Aging, Parkinson's Disease, and Models: What Are the Challenges?衰老、帕金森病与模型:面临哪些挑战?
Aging Biol. 2023;1. doi: 10.59368/agingbio.20230010. Epub 2023 Jul 28.
9
Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.富亮氨酸重复激酶在保护多巴胺能神经元存活中的细胞自主作用。
Elife. 2024 Jun 10;12:RP92673. doi: 10.7554/eLife.92673.
10
Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.短期脂多糖处理可导致LRRK2 G2019S基因敲入小鼠的星形胶质细胞活化,而多巴胺能神经元不会丢失。
Res Sq. 2024 Mar 21:rs.3.rs-4076333. doi: 10.21203/rs.3.rs-4076333/v1.
人类 LRRK2 转基因小鼠多巴胺能神经传递受损和微管相关蛋白 tau 改变。
Neurobiol Dis. 2010 Dec;40(3):503-17. doi: 10.1016/j.nbd.2010.07.010. Epub 2010 Jul 24.
4
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice.富含亮氨酸重复激酶2的缺失会导致老年小鼠蛋白质降解途径受损、α-突触核蛋白积累以及细胞凋亡。
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9879-84. doi: 10.1073/pnas.1004676107. Epub 2010 May 10.
5
GTPase activity plays a key role in the pathobiology of LRRK2.GTPase 活性在 LRRK2 的病理生物学中起着关键作用。
PLoS Genet. 2010 Apr 8;6(4):e1000902. doi: 10.1371/journal.pgen.1000902.
6
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.LRRK2 过表达增强了小鼠纹状体多巴胺传递和运动表现,而家族性帕金森病突变 G2019S 则消除了这种作用。
J Neurosci. 2010 Feb 3;30(5):1788-97. doi: 10.1523/JNEUROSCI.5604-09.2010.
7
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.富含亮氨酸重复激酶 2 调节帕金森病相关突变型 α-突触核蛋白诱导的神经病理学进展。
Neuron. 2009 Dec 24;64(6):807-27. doi: 10.1016/j.neuron.2009.11.006.
8
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).LRRK2 敲除小鼠对 MPTP(1-甲基-4-苯基-1,2,3,6-四氢吡啶)的超敏反应缺失出乎意料。
J Neurosci. 2009 Dec 16;29(50):15846-50. doi: 10.1523/JNEUROSCI.4357-09.2009.
9
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.富含亮氨酸重复激酶2(LRRK2)对埃兹蛋白/根蛋白/膜突蛋白的磷酸化作用促进了神经元形态发生过程中肌动蛋白细胞骨架的重排。
J Neurosci. 2009 Nov 4;29(44):13971-80. doi: 10.1523/JNEUROSCI.3799-09.2009.
10
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila.帕金蛋白可保护果蝇免受富含亮氨酸重复激酶2(LRRK2)G2019S突变体诱导的多巴胺能神经变性。
J Neurosci. 2009 Sep 9;29(36):11257-62. doi: 10.1523/JNEUROSCI.2375-09.2009.